HanchorBio Inc. 漢康生技股份有限公司

About HanchorBio Inc. 漢康生技股份有限公司

HanchorBio Inc. (TWSE: 7827) is a global clinical-stage biotechnology company developing next-generation immunotherapies for oncology and immune-mediated diseases. Our strategy is built around macrophage and myeloid biology. Through our proprietary Fc-Based Designer Biologics (FBDB™) platform, we engineer differentiated, multi-functional biologics designed to activate innate and adaptive immunity and address limitations of existing immunotherapies. HCB101, our lead clinical-stage program, is an engineered SIRPα-IgG4 Fc fusion protein designed to selectively block the CD47–SIRPα pathway while reducing red-blood-cell binding. By restoring macrophage-mediated tumor-cell clearance and supporting antigen presentation, HCB101 is being developed as a combination-ready macrophage immune backbone across selected solid tumors. HCB101 serves as HanchorBio’s clinical anchor. Clinical and translational learnings from the program guide rational combination strategies, expansion into additional tumor settings, and the development of next-generation multi-axis biologics through the FBDB™ platform. Our broader portfolio extends this approach across oncology and immune-mediated diseases, including multi-functional immunotherapies and programs exploring the therapeutic potential of myeloid biology beyond cancer. Headquartered in Taipei, with operations in Shanghai and the San Francisco Bay Area, HanchorBio brings together global clinical development, translational science, biologics engineering, CMC, regulatory, and partnering capabilities. Immunity was never one-dimensional. Neither are we.